Stryker (SYK) 주식 개요
스트라이커는 미국 및 전 세계에서 의료 기술 회사로 활동하고 있습니다. 자세히 보기
SYK Community Fair Values
Create NarrativeSee what 104 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$323.52
FV
1.4% 저평가 내재 할인율6.00%
Revenue growth p.a.
402
users have viewed this narrative5users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
Stryker Corporation 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$319.14 |
| 52주 최고가 | US$404.87 |
| 52주 최저가 | US$281.00 |
| 베타 | 0.78 |
| 1개월 변동 | 3.68% |
| 3개월 변동 | -2.49% |
| 1년 변동 | -17.60% |
| 3년 변동 | 9.77% |
| 5년 변동 | 21.10% |
| IPO 이후 변동 | 58,818.12% |
최근 뉴스 및 업데이트
Recent updates
Seeking Alpha • Jul 08
Stryker: Medtech On Sale, Benefiting From Industry Growth
Summary Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK’s adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth. Key risks include cybersecurity vulnerabilities and fierce competition, but SYK’s diversified portfolio and disciplined capital allocation underpin its long-term outlook. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Recovery Prospects
Stryker's fair value estimate has been adjusted slightly lower to $386.80 from $389.24 as analysts temper price targets in response to lower utilization expectations, inflation headwinds, and more conservative long term margin and P/E assumptions. Analyst Commentary Recent Street research on Stryker has been active, with most updates focused on resetting price targets and reassessing long term assumptions around utilization, inflation, and margins.내러티브 업데이트 • May 31
SYK: Hospital Digitization And Cyber Resilience Will Drive 2026 Rebound Potential
Analysts have trimmed Stryker's updated price target slightly, reflecting a minor change of about $0.11 and combining a series of recent target cuts from multiple firms with one modest increase, as they reassess assumptions around discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts who recently raised or affirmed higher targets highlight what they see as healthy fundamentals in U.S. medical technology, which they argue can support Stryker's growth assumptions that underpin current P/E expectations.내러티브 업데이트 • May 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Upside
Analysts have nudged Stryker's fair value estimate lower to about $389 from roughly $419, as a wave of reduced price targets led by firms like Truist, Barclays and others has been paired with updated assumptions for slightly lower future P/E multiples, alongside higher projected revenue growth and profit margins. Analyst Commentary Recent research around Stryker has tilted more cautious, with a cluster of reduced price targets across multiple firms, offset by a smaller group of more supportive views.분석 기사 • May 04
Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...내러티브 업데이트 • Apr 21
SYK: Diversified Portfolio And Hospital Digitization Will Support 2026 Upside
Analysts have trimmed Stryker's fair value estimate by about $6 to $419, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and a slightly lower future P/E multiple, even as profit margin expectations are marginally higher. Analyst Commentary Recent Street research on Stryker shows a mix of optimism about the company’s long term growth drivers and caution around near term valuation and risk.내러티브 업데이트 • Apr 06
SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside
The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.내러티브 업데이트 • Mar 22
SYK: Diversified Portfolio And Robotics Adoption Will Support 2026 Upside
Analysts have trimmed the Stryker fair value estimate by less than $1 to about $424 per share, reflecting a slightly higher discount rate and a modestly lower assumed future P/E multiple. Recent research cites mixed price target moves and differing views on near term catalysts and sector trends.내러티브 업데이트 • Mar 07
SYK: Diversified Product Reach And Robotics Expansion Will Support 2026 Upside
The analyst fair value estimate for Stryker has edged up by about $0.50 to $424.90, as analysts factor in recent price target moves, including several Outperform ratings that highlight the company's broader product reach and diversified growth profile. Analyst Commentary Recent research on Stryker reflects a mix of optimism about the company’s growth profile and some caution on valuation and sector level risks.내러티브 업데이트 • Feb 20
SYK: Diversified Medtech Portfolio And Robotics Execution Will Support 2026 Upside
Analysts made a modest trim to their blended Stryker price target, reflecting mixed recent revisions that range from higher targets up to $465 with Outperform ratings to lower targets near $390 and $399 with a Hold rating, as they weigh the company's broader product reach and expected sales and earnings trends against valuation and sector-level risks. Analyst Commentary Recent research on Stryker reflects a split view, with some analysts leaning into the growth story and others more guarded on valuation and sector risks.분석 기사 • Feb 09
Stryker's (NYSE:SYK) Earnings Seem To Be Promising
Stryker Corporation's ( NYSE:SYK ) recent earnings report didn't offer any surprises, with the shares unchanged over...분석 기사 • Feb 07
Stryker (NYSE:SYK) Is Due To Pay A Dividend Of $0.88
Stryker Corporation ( NYSE:SYK ) will pay a dividend of $0.88 on the 30th of April. This takes the annual payment to...내러티브 업데이트 • Feb 06
SYK: Orthopedics And Robotics Execution Will Support 2026 Rebound In Medtech Sentiment
Analysts have reduced their fair value estimate for Stryker by about $3 to $424, reflecting slightly softer revenue growth assumptions, a future P/E multiple closer to 34, and a modestly higher profit margin outlook following recent mixed price target changes across Wall Street. Analyst Commentary Recent research coverage on Stryker reflects a mix of optimism and caution, with several firms adjusting price targets and ratings in different directions.내러티브 업데이트 • Jan 22
SYK: Orthopedics And Robotics Execution Will Support 2026 Upside Potential
Analysts have inched their average price target on Stryker higher, with a modest fair value lift to about US$427.40, as they weigh mixed target changes across firms against ongoing views that the company remains a high quality large-cap MedTech name heading into 2026. Analyst Commentary Recent Street research on Stryker shows a split tape, with several firms lifting targets and ratings while others trim fair values or stay neutral.내러티브 업데이트 • Jan 08
SYK: Orthopedics Strength And Robotics Adoption Will Support Long-Term Upside
Narrative Update: Stryker The analyst price target for Stryker has been adjusted slightly lower to reflect a fair value estimate of about $427.22. Analysts point to mixed but generally solid recent research that highlights compressed forward multiples, updated targets in the $390 to $453 range, and ongoing views of Stryker as a high quality large cap MedTech name, with attractive entry points and healthy procedure and CapEx trends into 2026.내러티브 업데이트 • Dec 19
SYK: Expanding Orthopedics And Robotics Footprint Will Drive Long-Term Upside Potential
Analysts have modestly trimmed our fair value estimate for Stryker to approximately $428 from about $433 per share, reflecting a slightly higher discount rate and lower valuation multiple, even as they acknowledge improving revenue growth, rising profit margins, and continued operating leverage highlighted in recent research updates and investor day commentary. Analyst Commentary Street research on Stryker has been active in recent weeks, with modestly higher and lower price targets reflecting a balanced mix of optimism on execution and caution on MedTech sentiment and relative growth.분석 기사 • Dec 14
Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88
Stryker Corporation's ( NYSE:SYK ) periodic dividend will be increasing on the 30th of January to $0.88, with investors...분석 기사 • Sep 08
Does Stryker (NYSE:SYK) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Aug 08
Investors Can Find Comfort In Stryker's (NYSE:SYK) Earnings Quality
NYSE:SYK 1 Year Share Price vs Fair Value Explore Stryker's Fair Values from the Community and select yours The most...주주 수익률
| SYK | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | -3.7% | -1.8% | -1.4% |
| 1Y | -17.6% | -18.1% | 17.4% |
수익률 대 산업: SYK은 지난 1년 동안 -18.1%의 수익을 기록한 US Medical Equipment 산업과 동일한 성과를 보였습니다.
수익률 대 시장: SYK은 지난 1년 동안 17.4%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| SYK volatility | |
|---|---|
| SYK Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.2% |
안정적인 주가: SYK는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: SYK의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1941 | 56,000 | Kevin Lobo | www.stryker.com |
스트라이커 코퍼레이션은 미국 및 전 세계에서 의료 기술 기업으로 운영되고 있습니다. 이 회사는 메드서지 및 뉴로테크놀로지 부문과 정형외과 부문을 통해 운영되고 있습니다. 메드서지 및 신경공학 부문은 수술 장비, 환자 및 간병인 안전 기술, 내비게이션 시스템, 내시경 및 통신 시스템, 환자 처리, 응급 의료 장비 및 집중 치료 일회용 제품, 임상 커뮤니케이션 및 인공지능 지원 가상 치료 플랫폼 기술, 급성 허혈성 및 출혈성 뇌졸중과 정맥 혈전색전증 치료를 위한 최소 침습 제품, 전통적인 뇌 및 두개골 기반 수술 절차 제품, 합성 뼈 이식 및 척추 확대 제품을 포함한 정형외과 및 바이오수술 제품을 제공합니다.
Stryker Corporation 기초 지표 요약
| SYK 기초 통계 | |
|---|---|
| 시가총액 | US$122.63b |
| 순이익 (TTM) | US$3.34b |
| 매출 (TTM) | US$25.27b |
36.7x
주가수익비율(P/E)4.8x
주가매출비율(P/S)SYK는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| SYK 손익계산서 (TTM) | |
|---|---|
| 매출 | US$25.27b |
| 매출원가 | US$8.92b |
| 총이익 | US$16.35b |
| 기타 비용 | US$13.01b |
| 순이익 | US$3.34b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Jul 30, 2026
| 주당순이익(EPS) | 8.70 |
| 총이익률 | 64.70% |
| 순이익률 | 13.21% |
| 부채/자본 비율 | 64.1% |
SYK의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Stryker 배당 일정 | |
|---|---|
| 배당락일 | Jun 30 2026 |
| 배당 지급일 | Jul 31 2026 |
| 배당락일까지 남은 일수 | 21 days |
| 배당 지급일까지 남은 일수 | 10 days |
SYK는 안정적으로 배당을 지급합니까?
SYK 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/20 22:04 |
| 종가 | 2026/07/20 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Stryker Corporation는 53명의 분석가가 다루고 있습니다. 이 중 26명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Matthew Miksic | Barclays |